Drugs of the Future

Papers
(The median citation count of Drugs of the Future is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
American Association for Cancer Research (AACR) - 113th Annual Meeting. New Orleans/Virtual - April 8-13, 20226
Lisavanbulin. Microtubule destabilizer (tubulin polymerization inhibitor), Tumor checkpoint controller, Treatment of advanced glioblastoma multiforme4
An overview of prophylaxis and treatment indications for COVID-19-related thrombotic complications3
Pipeline on the Move3
Pipeline on the Move2
American Society of Hematology - 64th Annual Meeting and Exposition. New Orleans - December 10-13, 20222
American Academy of Neurology (AAN) - 74th Annual Meeting: The Great Neuro Reunion. Seattle - April 2-7, 20222
NME Digest2
NME Digest2
Therapeutic targets for giant cell arteritis1
IDWeek 2022. Washington, D.C. - October 19-23, 20221
Ancremonam. Monobactam, Treatment of multidrug-resistant Enterobacteriaceae infections1
Experimental and in silico approaches to target selection and tractability for drug discovery. Highlights from the Society for Medicines Research Confer1
NCX-470. Nitric oxide-donating prostaglandin analogue, Treatment of glaucoma, Treatment of ocular hypertension1
Therapeutic targets for dermatomyositis1
Pipeline on the Move1
American Heart Association (AHA) Scientific Sessions - 2022 Annual Meeting. Chicago/Virtual - November 5-7, 20221
Imlunestrant. Selective estrogen receptor degrader (SERD), Treatment of breast cancer1
Pipeline on the Move1
Tanfanercept. Recombinant variant of human TNFR1, TNF-α modulator, Treatment of dry eye disease0
Pipeline on the Move0
Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 20220
BIO-Europe Spring Digital 2022 – 16th Annual Partnering Conference. Virtual – March 28-31, 20220
Pipeline on the Move0
Tebipenem pivoxil hydrobromide. Penicillin-binding protein (PBP) (bacterial) inhibitor, Carbapenem antibiotic, Treatment of urinary tract infections0
Gene therapy in the fight against pediatric blood disorders: sickle cell disease and β-thalassemia0
Pipeline on the Move0
European Association of Nuclear Medicine – 35th Annual Congress. Barcelona – October 15-19, 20220
AACR-NCI-EORTC - 34th International Symposium on Molecular Targets and Cancer Therapeutics. Barcelona - October 26-28, 20220
Lenadogene nolparvovec. rAAV2 gene therapy vector encoding ND4, Treatment of Leber hereditary optic neuropathy0
Cefepime/enmetazobactam. β-Lactam/β-lactamase inhibitor, Treatment of complicated urinary tract infection0
European Society of Medical Oncology (ESMO) - 2022 Annual Congress. Paris/Virtual - September 9-13, 20220
Pruxelutamide. Androgen receptor antagonist, Treatment of metastatic castration-resistant prostate cancer, Treatment of metastatic breast cancer0
Tinlarebant. Retinol-binding protein 4 (RBP4) inhibitor, Treatment of Stargardt disease, Treatment of dry age-related macular degeneration0
Navafenterol. Dual M3 receptor antagonist/β2-adrenoceptor agonist (MABA), Treatment of chronic obstructive pulmonary disease0
Efanesoctocog alfa. Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein, Treatment of hemophilia A0
Pipeline on the Move0
Alzheimer's Association International Conference (AAIC) 2022. San Diego – July 31-August 4, 20220
Association for Research in Vision and Ophthalmology (ARVO) - 2022 Annual Meeting. Denver/Virtual - May 1-4 and 11-12, 20220
Glofitamab. Anti-CD20 T-cell–engaging bispecific antibody, Treatment of non-Hodgkin lymphoma0
Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease0
Recent Clinical Disclosures and SMR Award. Highlights from the Society for Medicines Research Conference. Virtual - December 2, 20210
Sabatolimab. TIM-3-targeting monoclonal antibody, Treatment of myelodysplastic syndrome, Treatment of acute myeloid leukemia0
RGX-314. AAV8 gene therapy encoding anti-VEGF Fab, Treatment of wet age-related macular degeneration, Treatment of diabetic retinopathy0
Biomarkers in frontotemporal dementia: a narrative review0
Association for Cancer Immunotherapy (CIMT) - 19th Annual Meeting. Mainz/Virtual - May 10-12, 20220
Tolebrutinib. Bruton tyrosine kinase (BTK) inhibitor, Treatment of multiple sclerosis0
American Society of Clinical Oncology (ASCO) – 58th Annual Meeting. Chicago/Virtual – June 3-7, 20220
Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity0
NME Digest0
Innovative new pharma and biotech partnerships: How is the landscape transforming? Highlights from the Society for Medicines Research Conference. Steven0
European Respiratory Society - 32nd International Congress. Barcelona - September 4-6, 20220
Cefepime/taniborbactam. Fixed-dose combination, Cephalosporin beta-lactam antibiotic/beta-lactamase inhibitor, Treatment of complicated urinary tract in0
Furaprevir. HCV NS3/4A protease inhibitor, Treatment of chronic hepatitis C virus infection0
Gene therapies for achromatopsia under clinical evaluation0
Society for the Study of Inborn Errors of Metabolism – 2022 Annual Symposium. Freiburg – August 30-September 2, 20220
Zandelisib. Phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, Treatment of B-cell lymphomas0
The Liver Meeting 2022 - American Association for the Study of Liver Diseases (AASLD). 73rd Annual Meeting. Washington, D.C. - November 4-8, 20220
Tavokinogene telsaplasmid. DNA-based interleukin-12 (IL-12), Gene therapy, Treatment of metastatic melanoma, Treatment of triple-negative breast cancer,0
Adagrasib. GTPase KRAS (G12C mutant) inhibitor, Treatment of non-small cell lung cancer, Treatment of colorectal cancer0
Targets to watch in neuroinflammation: focus on RIPK10
Erfonrilimab. Bispecific anti-PD-L1/CTLA-4 antibody, Cancer immunotherapy0
Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity0
32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Lisbon/Virtual - April 23-26, 20220
American Society of Gene and Cell Therapy (ASGCT) – 25th Annual Meeting. Washington, D.C./Virtual - May 16-19, 20220
American Society for Clinical Pharmacology and Therapeutics – 123rd Annual Meeting. Virtual – March 16-18, 20220
Uproleselan sodium. E-selectin antagonist, Treatment of acute myeloid leukemia0
Lenzilumab. Anti-GM-CSF monoclonal antibody, Treatment of chronic myelomonocytic leukemia, Treatment of COVID-190
Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma0
American Chemical Society (ACS) – 264th National Meeting and Exposition. Chicago/Virtual – August 21-25, 20220
Crovalimab. Anti-C5 monoclonal antibody, Treatment of paroxysmal nocturnal hemoglobinuria, Treatment of atypical hemolytic uremic syndrome, Treatment of0
Pipeline on the Move0
Taletrectinib adipate. Dual ROS1 and NTRK inhibitor, Treatment of non-small cell lung cancer, Treatment of solid tumors0
International Association for the Study of Lung Cancer (IASLC) – 23rd World Conference on Lung Cancer (WCLC 2022). Vienna – August 6-9, 20220
European Association for Cancer Research (EACR) – 28th Annual Meeting. Seville – June 20-23, 20220
Sonelokimab. Interleukin-17A and -F nanobody, Treatment of moderate to severe psoriasis, Treatment of hidradenitis suppurativa0
American Chemical Society – 263rd National Meeting and Exposition. Virtual/San Diego – March 20-24, 20220
Society for Immunotherapy of Cancer (SITC) – 37th Annual Meeting. Boston/Virtual – November 8-12, 20220
Repotrectinib. ALK/ROS1/TRK inhibitor, Treatment of solid tumors0
European Federation of Medicinal Chemistry - XXVII International Symposium on Medicinal Chemistry (EFMC-ISMC 2022). Nice - September 4-8, 20220
Spesolimab. Anti-IL-36R monoclonal antibody, Treatment of generalized pustular psoriasis, Treatment of immune-mediated inflammatory diseases0
American Society of Nephrology's (ASN) Kidney Week - 2022 Annual Meeting. Orlando - November 3-6, 20220
Xeruborbactam. Ultrabroad-spectrum β-lactamase inhibitor, Treatment of bacterial infections0
American Society for Microbiology (ASM) Microbe – 2022 Annual Meeting. Washington, D.C. – June 9-13, 20220
Nafithromycin. Ketolide antibiotic, Treatment of community-acquired bacterial pneumonia0
Pozelimab/cemdisiran. Complement protein C5 inhibitor, Treatment of complement-mediated diseases0
Positioning of hafnium oxide nanoparticles therapy in cancer treatment0
Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2− and HER2+ advanced breast cancer0
European Association for the Study of Diabetes (EASD) – 58th Annual Meeting. Stockholm/Virtual – September 19-23, 20220
Pipeline on the Move0
0.095097064971924